552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in...

by Yuhong Zhang, Akito Nakamura, Keli Song, Stephen Grossman, Kristina Xega, Allison Berger, Gary Shapiro, Dennis Huszar
Published 2020-11-01

Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology

by Mary E. Loveless, Deborah Lawson, Michael Collins, Murali V. Prasad Nadella, Corinne Reimer, Dennis Huszar, Jane Halliday, John C. Waterton, John C. Gore, Thomas E. Yankeelov
Published 2012-01-01

The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis

by Qing Chang, Eirini Bournazou, Pasquale Sansone, Marjan Berishaj, Sizhi Paul Gao, Laura Daly, Jared Wels, Till Theilen, Selena Granitto, Xinmin Zhang, Jesse Cotari, Mary L. Alpaugh, Elisa de Stanchina, Katia Manova, Ming Li, Massimiliano Bonafe, Claudio Ceccarelli, Mario Taffurelli, Donatella Santini, Gregoire Altan-Bonnet, Rosandra Kaplan, Larry Norton, Norihiro Nishimoto, Dennis Huszar, David Lyden, Jacqueline Bromberg
Published 2013-07-01